IN006 is a bivalent RSV vaccine based on the company's mRNA and LNP platforms. The company reported completion of Phase 2 enrollment and vaccination in 2025; IN026 received FDA IND clearance in 2026.
2022 · Series B (historical disclosure) · $120 million ↗
Historical disclosure does not rule out subsequent financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
IN006 is a bivalent RSV vaccine based on the company's mRNA and LNP platforms. The company reported completion of Phase 2 enrollment and vaccination in 2025; IN026 received FDA IND clearance in 2026.
Program / service
Target / indication
Representative stage
Evidence & scope
IN006
RSV-A / RSV-B prefusion F antigens · Prevention of RSV infection
Phase 2 (IN006; company disclosure)
Refer to the program-specific stage source. This record does not include unverified cross-trial results or efficacy rankings.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Moderna announced Canadian authorization of mFLUSIVA, its mRNA influenza vaccine, and mCOFLU, its combined influenza and COVID-19 vaccine, for adults 50 and older. The November 5 announcement cites Phase 3 efficacy evidence for mFLUSIVA and immunogenicity comparisons for mCOFLU. The company said it would engage Canadian authorities and immunization partners on future availability.
